OncoMatch/Clinical Trials/NCT04834544
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
Is NCT04834544 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies DCVAC/OvCa for epithelial ovarian carcinoma.
Treatment: DCVAC/OvCa — This is a randomized, double-blind, placebo-controlled,parallel-group preliminary verifying study about safety and efficacy of maintenance DCVAC/OvCa after first-line chemotherapy added to standard of care in patients with newly diagnosed FIGO III-IV ovarian, fallopian tube, or primary peritoneal carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 any mutation
Required: BRCA2 any mutation
Disease stage
Required: Stage III, IV
Grade: high-grade seroushigh-grade endometrioid
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: platinum-based chemotherapy
Exception: already started after surgery
First-line Pt-based adjuvant chemotherapy already started after surgery
Cannot have received: radiation therapy
Exception: previous or concurrent radiotherapy to the abdomen and pelvis
Previous or concurrent radiotherapy to the abdomen and pelvis
Cannot have received: immunotherapy
Use of any immunotherapy in the past (e.g., anti-PD-1/PD-L1 or other immune checkpoint inhibitors, therapeutic vaccines, adoptive cell therapy, cytokines)
Lab requirements
Blood counts
WBC >4000/mm3; neutrophil count >1500/mm3; hemoglobin ≥8 g/dL; platelet count ≥100,000/mm3
Kidney function
Serum creatinine <2× ULN; blood urea nitrogen <2× ULN
Liver function
Total bilirubin <2× ULN (benign hereditary hyperbilirubinemias permitted); ALT, AST <2× ULN
Cardiac function
No clinically significant cardiovascular disease (see exclusion 10.4); ejection fraction <40% excluded
Laboratory criteria: WBC >4000/mm3; neutrophil count >1500/mm3; hemoglobin ≥8 g/dL; platelet count ≥100,000/mm3; total bilirubin <2× ULN (benign hereditary hyperbilirubinemias permitted); ALT, AST, creatinine <2×ULN; blood urea nitrogen <2×ULN. Adequate coagulation parameters: aPTT ≤1.5×ULN; INR ≤1.5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04834544 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require BRCA1?
Yes, BRCA1 any mutation is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 any mutation is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages